Community-acquired pneumonia in adults: Initial antibiotic therapy

American Family Physician

Volumn 56, Issue 2, 1997, Pages 544-550

  King, Dana E ^a   Pippin Jr , H Joel ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DIRITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; MACROLIDE; MEROPENEM; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; PNEUMOCOCCUS VACCINE; TIMENTIN; VANCOMYCIN;

ADULT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CAUSE OF DEATH; CLINICAL FEATURE; COMORBIDITY; DRUG MIXTURE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PNEUMONIA; REVIEW;

ADULT; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MICROBIAL; HOSPITALIZATION; HUMANS; PNEUMONIA; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 0030752898     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Garibaldi RA. Epidemiology of community-acquired respiratory tract infections in adults. Incidence, etiology, and impact. Am J Med 1985;78:32-7.
2. Niederman MS, Bass JB Jr, Campbell GD, Fein AM, Grossman RF, Mandell LA, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis 1993;148:1418-26.
3. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995;333:1618-24.
4. Sue DY. Community-acquired pneumonia in adults. West J Med 1994;161:383-9.
5. File TM Jr, Tan JS, Plouffe JF. Community-acquired pneumonia. What's needed for accurate diagnosis. Postgrad Med 1996;99(1):95-102, 105-7.
6. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50.
7. Hasley PB, Albaum MN, Li YH, Fuhrman CR, Britton CA, Marrie TJ, et al. Do pulmonary radiographic findings at presentation predict mortality in patients with community-acquired pneumonia? Arch Intern Med 1996;156:2206-12.
8. Fang GD, Fine M, Orloff J, Arisumi D, Yu VL, Kapoor W, et al. New and emerging etiologies for community-acquired penumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine 1990;69:307-16.
9. Lieberman D, Porath A, Schlaeffer F, Lieberman D, Boldur I. Legionella species community-acquired pneumonia. A review of 56 hospitalized adult patients. Chest 1996;109(5):1243-9.
10. Marrie TJ. Community-acquired pneumonia. Clin Infect Dis 1994;18:501-13.
11. Troy CJ, Peeling RW, Ellis AG, Hockin JC, Bennett DA, Murphy MR, et al. Chlamydia pneumoniae as a new source of infectious outbreaks in nursing homes. JAMA 1997;277:1214-8.
12. Tenover FC, Hughes JM. The challenges of emerging infectious diseases. Development and spread of multiply-resistant bacterial pathogens. JAMA 1996;275:300-4.
13. Mandell LA. Antibiotics for pneumonia therapy. Med Clin North Am 1994;78:997-1014.
14. Pallares R, Gudiol F, Linares J, Ariza J, Rufi G, Murgui L, et al. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. N Engl J Med 1987;317:18-22.
15. Appelbaum PC. New prospects for antibacterial agents against multidrug-resistant pneumococci. Microb Drug Resist 1995;1:43-8.
16. Jorgensen JH, Doern GV, Maher LA, Howell AW, Redding JS. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 1990;34:2075-80.
17. Butler JC, Hofmann J, Cetron MS, Elliott JA, Facklam RR, Breiman RF. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Center for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. J Infect Dis 1996;174:986-93.
18. Chien SM, Pichotta P, Siepman N, Chan CK. Treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing clarithromycin with erythromycin. Canada-Sweden Clarithromycin-Pneumonia Study Group. Chest 1993;103:697-701.
19. Pomilla PV, Brown RB. Outpatient treatment of community-acquired pneumonia in adults. Arch Intern Med 1994;154:1793-802.
20. Joshi N, Milfred D. The use and misuse of new antibiotics. A perspective. Arch Intern Med 1995; 155:569-77.
21. The choice of antibacterial drugs. Med Lett Drugs Ther 1996; 38(971):25-34.
22. Mouton Y, Leroy O, Beuscart C, Chidiac C, Senneville E, Ajana F, et al. Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections. J Antimicrob Chemother 1993;31(Suppl A):87-95.
23. Levison ME, Mangura CT, Lorber B, Abrutyn E, Pesanti EL, Levy RS, et al. Clindamycin compared with penicillin for the treatment of anaerobic lung abscess. Ann Intern Med 1983;98:466-71.
24. Frieden TR, Mangi RJ. Inappropriate use of oral ciprofloxacin. JAMA 1990;264:1438-40.
25. Sparfloxacin and levofloxacin. Med Lett Drugs Ther 1997;39(999):41-3.
26. Ramirez JA. Switch therapy in adult patients with pneumonia. Clin Pulmonary Med 1995;2(6):327-33.
27. Siegel RE, Halpern NA, Almenoff PL, Lee A, Cashin R, Greene JG. A prospective randomized study of inpatient iv. antibiotics for community-acquired pneumonia. The optimal duration of therapy. Chest 1996;110:965-71.